Pentoxifylline alleviates hypertension in metabolic syndrome: Effect on low-grade inflammation and angiotensin system

Journal of Endocrinological Investigation

Volumn 38, Issue 4, 2015, Pages 437-445

  Azhar, A ^a   El Bassossy, H M ^b,c  

^a King Abdulaziz University   (Saudi Arabia)

^b Zagazig University   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Hypertension; Insulin resistance; Pentoxifylline; Vascular

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC TISSUE; ARTICLE; BODY SURFACE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE ADHESION; WEIGHT GAIN; ANIMAL; DISEASE MODEL; DRUG EFFECTS; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION; INFLAMMATION; MALE; METABOLIC SYNDROME X; PENTOXIFYLLINE; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; VASODILATOR AGENTS;

EID: 84941791474     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0209-z     Document Type: Article

References (40)

1. Kolovou GD, Anagnostopoulou KK, Cokkinos DV (2005) Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81:358-366
2. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7
3. Navab M, Gharavi N, Watson AD (2008) Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 11:459-464
4. Frigolet ME, Torres N, Tovar AR (2013) The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 24:2003-2015
5. Reilly DT, Quinton DN, Barrie WW (1987) A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J 100:445-447
6. Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187:447-463
7. El-Bassossy HM, El-Moselhy MA, Mahmoud MF (2011) Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition. Naunyn Schmiedebergs Arch Pharmacol 384:277-285
8. Azhar A, El-Bassossy HM (2014) Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance. PLoS One 9:e98281
9. Huang ZS, Lee TK (1991) Comparison of in vitro platelet aggregation and its inhibition by three antithrombotic drugs between human and guinea pig. Proc Natl Sci Counc Repub China B 15:8-14
10. Weithmann KU, Just M, Schlotte V, Seiffge D (1989) Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro. Vasa 18:273-276
11. Lenoble G (1989) New aspects of the pharmacology of pentoxifylline. J Mal Vasc 14 (Suppl A):35-41
12. Herskovits E, Famulari A, Tamaroff L, Gonzalez AM, Vazquez A, Dominguez R, Fraiman H, Vila J (1985) Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol 24:73-81
13. Seiffge D, Kremer E (1984) Antithrombotic effects of pentoxifylline on laser-induced thrombi in rat mesenteric arteries. IRCS Med Sci 12:91-92
14. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625-F631
15. El-Bassossy H, Dsokey N, Fahmy A (2014) Characterization of vascular complications in experimental model of fructose induced metabolic syndrome. Toxicol Mech Methods, pp 1-8. doi: 10.3109/15376516.2014.945109
16. Field KJ, White WJ, Lang CM (1993) Anaesthetic effects of chloral hydrate, pentobarbitone and urethane in adult male rats. Lab Anim 27:258-269
17. Radovits T, Bomicke T, Kokeny G, Arif R, Loganathan S, Kecsan K, Korkmaz S, Barnucz E, Sandner P, Karck M, Szabo G (2009) The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 156:909-919
18. Hassan N, El-Bassossy HM, Zakaria MNM (2013) Heme oxygenase-1 induction protects against hypertension associated with diabetes: effect on exaggerated vascular contractility. Naunyn Schmiedebergs Arch Pharmacol 386:217-226
19. Hassan NA, El-Bassossy HM, Mahmoud MF, Fahmy A (2014) Caffeic acid phenethyl ester, a 5-lipoxygenase enzyme inhibitor, alleviates diabetic atherosclerotic manifestations: effect on vascular reactivity and stiffness. Chem Biol Interact 213:28-36
20. Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A (2013) Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS One 8:1-11
21. El-Bassossy HM, Fahmy A, Badawy D (2011) Cinnamaldehyde protects from the hypertension associated with diabetes. Food Chem Toxicol 49:3007-3012
22. El-Bassossy HM, El-Fawal R, Fahmy A, Watson ML (2013) Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol 169:693-703
23. Rowell LB (1993) Human cardiovascular control. Oxford University Press, New York
24. Hulin I, Kinova S, Paulis L, Slavkovsky P, Duris I, Mravec B (2010) Diastolic blood pressure as a major determinant of tissue perfusion: potential clinical consequences. Bratislavsk-Ñ lek-Érske listy 111: 54-56
25. Strandberg TE, Pitkala K (2003) What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens 12:293-297
26. Raptis S, Mitrakou A, Hadjidakis D, Diamantopoulos E, Anastasiou C, Fountas A, Muller R (1987) 24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas. Acta Diabetol Lat 24:181-192
27. Flint H, Cotter MA, Cameron NE (2000) Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. Int J Exp Diabetes Res 1:49-58
28. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-823
29. Mahmoud MF, El-Nagar M, El-Bassossy HM (2012) Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats. Arch Pharm Res 35:155-162
30. Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PRL, Passos S (2014) Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 90:617-620
31. Goicoechea M, Garcia de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, Panizo N, Verde E, Munoz MA, Luno J (2012) Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 25:969-975
32. Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P, Gomez-Navarro B, Cueto-Manzano AM (2012) Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transpl 27:2023-2028
33. Maiti R, Agrawal NK, Dash D, Pandey BL (2007) Effect of pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vasc Pharmacol 47:118-124
34. Fernandes JL, de Oliveira RT, Mamoni RL, Coelho OR, Nicolau JC, Blotta MH, Serrano CV (2008) Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - a randomized placebo-controlled study. Atherosclerosis 196:434-442
35. Ghorbani A, Omidvar B, Beladi-Mousavi SS, Lak E, Vaziri S (2012) The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 32:790-796
36. Kang YM, Wang Y, Yang LM, Elks C, Cardinale J, Yu XJ, Zhao XF, Zhang J, Zhang LH, Yang ZM, Francis J (2010) TNF-α in hypothalamic paraventricular nucleus contributes to sympathoexcitation in heart failure by modulating AT1 receptor and neurotransmitters. Tohoku J Exp Med 222:251-263
37. Guggilam A, Patel KP, Haque M, Ebenezer PJ, Kapusta DR, Francis J (2008) Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail 10:625-634
38. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Chahin J, Mendez ML, Gallego E, Macia M, del Castillo N, Rivero A, Getino MA, Garcia P, Jarque A, Garcia J (2014) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol ASN [Epub ahead of print]
39. Kabbesh N, Gogny M, Chatagnon G, Noireaud J, Thorin C, Desfontis JC, Mallem MY (2012) Vasodilatory effect of pentoxifylline in isolated equine digital veins. Vet J 192:368-373
40. Greenberg A, Piraino BH, Kroboth PD, Weiss J (1984) Severe theophylline toxicity. Role of conservative measures, antiarrhythmic agents, and charcoal hemoperfusion. Am J Med 76:854-860